Stockscreener 앱 받기
2.01
9.05%
-0.20
전일 마감가:
$2.21
열려 있는:
$2.275
하루 거래량:
5.33M
Relative Volume:
0.33
시가총액:
$251.79M
수익:
-
순이익/손실:
$-112.46M
주가수익비율:
-1.2256
EPS:
-1.64
순현금흐름:
$-99.89M
1주 성능:
-15.90%
1개월 성능:
+736.50%
6개월 성능:
+47.80%
1년 성능:
+117.71%
1일 변동 폭
$1.98
$2.31
1주일 범위
$1.92
$2.65
52주 변동 폭
$0.1311
$3.29
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
VOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
2.015 | 298.65M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.70 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.76 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.81 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
565.44 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.80 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
Vor Biopharma Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Is Vor Biopharma Inc. a good long term investmentExplosive portfolio gains - jammulinksnews.com
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target - MSN
What analysts say about Vor Biopharma Inc. stockRapid return acceleration - Autocar Professional
What drives Vor Biopharma Inc. stock priceExceptional trading performance - Jammu Links News
Vor Biopharma's Strategic Turnaround and the Case for Immediate Investment - AInvest
Vor Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio Awards Massive 5.3M Share Package to New Development Chief: Full Grant Details Revealed - Stock Titan
Vor Biopharma shares rise 2.52% premarket after appointing Qing Zuraw as Chief Development Officer. - AInvest
Why Vor Biopharma Inc. stock is on top investor watchlistsFree Real-Time Market Predictions - Newser
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Yahoo Finance
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
Vor Biopharma Inc. shares rise 2.00% premarket after Bonesupport CEO predicts strong growth. - AInvest
How Vor Biopharma Inc. stock performs during market volatilitySafe Entry High Exit Alerts - Newser
What makes Vor Biopharma Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - newser.com
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
VOR’s 2025 Market Dance: Up 174.66% – Time to Invest? - investchronicle.com
Vor Biopharma Explodes 22% – What’s Fueling the Surge? - AInvest
Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer - MarketScreener
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer - The Manila Times
Vor Bio Strengthens Leadership: Top Biotech Executive Who Raised $6B Joins as New CFO/CBO - Stock Titan
Vor Biopharma shares rise 5.83% intraday after $41B telitacicept licensing deal and HC Wainwright upgrade. - AInvest
Vor Biopharma Sees Unusually High Options Volume (NYSE:VOR) - Defense World
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
VOR’s Unexpected Surge: What’s Driving the Spike? - timothysykes.com
VOR Biopharma Inc. Faces Uncertain Future Amid Recent Developments - StocksToTrade
Vor Biopharma Soars 19.1% on Analyst Upgrade - AInvest
Vor Biopharma Stock Skyrockets: What’s Next? - StocksToTrade
Vor Biopharma shares surge 28.01% intraday after licensing telitacicept for autoimmune diseases and raising $1.75B in private funding. - AInvest
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by HC Wainwright - Defense World
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Massive CEO Stock Grant: Vor Bio Awards 83M Shares to New Chief Executive at $0.89 - Stock Titan
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market - Benzinga
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):